Caswell Stephen, Craigie Angela M, Wardle Jane, Stead Martine, Anderson Annie
Centre for Research into Cancer Prevention and Screening, Medical Research Institute, Population Health Sciences Division, University of Dundee, Dundee, UK.
BMJ Open. 2012 May 25;2(3). doi: 10.1136/bmjopen-2012-001276. Print 2012.
The BeWEL study is aimed at assessing the impact of a personalised lifestyle programme on body weight in people at risk of developing colorectal adenomas. The study is a two-arm multicentre randomised controlled trial comparing the BeWEL lifestyle programme against usual care. Over 12 months, 316 people who have had a colorectal adenoma removed through the national screening programme will be randomised to provide 80% power to detect a weight loss (primary outcome) of 7% over 12 months.
The 12-month intervention will be delivered by lifestyle counsellors via three face-to-face visits followed by nine monthly telephone support calls. Consultant endorsement for the study will be stressed. An individualised caloric prescription based on estimates for weight maintenance -600 kcal will be calculated. Motivational interviewing techniques will be used to identify personal motivations for weight change and ways to improve perceived self-efficacy. The programme will utilise personalised diet and physical activity data from baseline measures to set behavioural goals. A range of behavioural strategies will be employed to support lifestyle change including goal setting, identifying specific implementation intentions, self-monitoring and feedback. Emphasis will be placed on self-monitoring body weight, and weighing scales will be provided. Programme acceptability will be explored postintervention with indepth interviews. Compliance and impact will be assessed by baseline and follow-up measures of diet by self-report, activity by accelerometry and anthropometry.
Ethical approval has been obtained from the Tayside Committee on Medical Research Ethics. Dissemination of results will focus on publications in peer-reviewed journals, presentations at national/international cancer meetings and NHS groups. In addition, the work will be communicated to the public through forums such at The Scottish Cancer Prevention Network (http://www.cancerpreventionscotland.co.uk/). The trial is registered with Current Controlled Trials (International Standard Randomised Controlled Trials No: ISRCTN53033856).
BeWEL研究旨在评估个性化生活方式计划对有患结直肠腺瘤风险人群体重的影响。该研究是一项双臂多中心随机对照试验,将BeWEL生活方式计划与常规护理进行比较。在12个月内,316名通过国家筛查计划切除了结直肠腺瘤的人将被随机分组,以提供80%的检验效能,来检测12个月内7%的体重减轻(主要结局)。
为期12个月的干预将由生活方式顾问通过三次面对面访问,随后进行九次每月一次的电话支持访问来实施。将强调研究得到顾问认可。将根据维持体重估计值 - 600千卡来计算个性化热量处方。将使用动机访谈技术来确定体重改变的个人动机以及提高自我效能感的方法。该计划将利用基线测量中的个性化饮食和身体活动数据来设定行为目标。将采用一系列行为策略来支持生活方式改变,包括目标设定、确定具体的实施意图、自我监测和反馈。将重点放在自我监测体重上,并提供体重秤。干预后将通过深入访谈探讨计划的可接受性。将通过自我报告的饮食基线和随访测量、加速度计测量的活动以及人体测量来评估依从性和影响。
已获得泰赛德医学研究伦理委员会的伦理批准。结果传播将侧重于在同行评审期刊上发表、在国家/国际癌症会议以及国民保健服务组织中的报告。此外,这项工作将通过诸如苏格兰癌症预防网络(http://www.cancerpreventionscotland.co.uk/)等论坛向公众传达。该试验已在当前对照试验注册(国际标准随机对照试验编号:ISRCTN53033856)。